Assignee
MARINUS PHARMACEUTICALS INC
US·14 granted patents·22 pending applications·58 citations·filing 2010–2024
Top patents by PatentIndex Score
36 records- 0196US10391105B2Methods of treating certain depressive disorders and delirium tremensMARINUS PHARMACEUTICALS INC·Filed 2017·Granted Aug 27, 2019·13 cites·14 claims
- 0295US11000531B2Methods of treating certain depressive disorders and delirium tremensMARINUS PHARMACEUTICALS INC·Filed 2020·Granted May 11, 2021·4 cites·23 claims
- 0395US8362286B2Method for making 3α-hydroxy, 3β- substituted-5α-pregnan-20-onesMARINUS PHARMACEUTICALS INC·Filed 2010·Granted Jan 29, 2013·17 cites·23 claims
- 0494US12115169B2Ganaxolone for use in treating tuberous sclerosis complex and seizure disordersMARINUS PHARMACEUTICALS INC·Filed 2024·Granted Oct 15, 2024·3 cites·24 claims
- 0594US11980625B2Ganaxolone for use in treating tuberous sclerosis complexMARINUS PHARMACEUTICALS INC·Filed 2023·Granted May 14, 2024·4 cites·25 claims
- 0694US11701367B2Ganaxolone for use in treating tuberous sclerosis complexMARINUS PHARMACEUTICALS INC·Filed 2022·Granted Jul 18, 2023·4 cites·25 claims
- 0792US11110100B2Ganaxolone for use in treatment of status epilepticusMARINUS PHARMACEUTICALS INC·Filed 2021·Granted Sep 7, 2021·3 cites·21 claims
- 0892US10639317B2Methods of treating certain depressive disorders and delirium tremensMARINUS PHARMACEUTICALS INC·Filed 2018·Granted May 5, 2020·5 cites·20 claims
- 0990US10780099B2Injectable neurosteroid formulations containing nanoparticlesMARINUS PHARMACEUTICALS INC·Filed 2016·Granted Sep 22, 2020·3 cites·22 claims
- 1088US11071740B2Method of treatment using nanoparticulate ganaxolone formulationsMARINUS PHARMACEUTICALS INC·Filed 2018·Granted Jul 27, 2021·1 cites·28 claims
- 1187US12268696B2Ganaxolone for use in treating tuberous sclerosis complex and seizure disordersMARINUS PHARMACEUTICALS INC·Filed 2024·Granted Apr 8, 2025·0 cites·22 claims
- 1287US12246026B2Ganaxolone for use in treatment of status epilepticusMARINUS PHARMACEUTICALS INC·Filed 2021·Granted Mar 11, 2025·1 cites·26 claims
- 1386US2025325562A1Intravenous Ganaxolone Formulations and Methods of Use in Treating Status Epilepticus and Other Seizure DisordersMARINUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1484US2025032512A1Ganaxolone for use in treating tuberous sclerosis complex and seizure disordersMARINUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1582US2024016817A1Intravenous Ganaxolone Formulations and Methods of Use in Treating Status Epilepticus and Other Seizure DisordersMARINUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1680US2023293549A1Intravenous ganaxolone formulations and methods of use in treating status epilepticus and other seizure disordersMARINUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1780US2023405021A1Ganaxolone for use in treatment of status epilepticusMARINUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1878US11679117B2Ganaxolone for use in treatment of status epilepticusMARINUS PHARMACEUTICALS INC·Filed 2022·Granted Jun 20, 2023·0 cites·28 claims
- 1978US2025082651A1Ganaxolone for use in treating genetic epileptic disordersMARINUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2077US2024374614A1Ganaxolone for use in treating tuberous sclerosis complexMARINUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2176US2023181600A1Injectable neurosteroid formulations containing nanoparticlesMARINUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2275US2025032510A1Amorphous solid dispersion ganaxolone formulationMARINUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2373US2023390305A1Amorphous solid dispersion ganaxolone formulationMARINUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2470US2022249515A1Ganaxolone for use in treating genetic epileptic disordersMARINUS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2567US2025034201A1Prodrugs of ganaxoloneMARINUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2665US11266662B2Ganaxolone for use in prophylaxis and treatment of postpartum depressionMARINUS PHARMACEUTICALS INC·Filed 2019·Granted Mar 8, 2022·0 cites·20 claims
- 2765US2021128583A1Injectable neurosteroid formulations containing nanoparticlesMARINUS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2864US2019160078A1Ganaxolone for use in treating genetic epileptic disordersMARINUS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2962US2024245709A1Ganaxolone for use in treatment of established status epilepticusMARINUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3061US2025032511A1Ganaxolone for use in treatment of super refractory status epilepticusMARINUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3160US2023321117A1Use of ganaxolone in treating an epilepsy disorderMARINUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3259US2023364109A1Ganaxolone for use in treatment of super refractory status epilepticusMARINUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3353US2016228454A1Intravenous ganaxolone formulations and methods of use in treating status epilepticus and other seizure disordersMARINUS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3448US2018296487A1Sustained release injectable neurosteroid formulationsMARINUS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3547US2019321375A1Method of administering a neurosteroid to effect electroencephalographic (eeg) burst suppressionMARINUS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3644US2019111059A1Compositions and methods for treating autism spectrum disorderMARINUS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when MARINUS PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →